JPWO2020025703A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020025703A5 JPWO2020025703A5 JP2021529521A JP2021529521A JPWO2020025703A5 JP WO2020025703 A5 JPWO2020025703 A5 JP WO2020025703A5 JP 2021529521 A JP2021529521 A JP 2021529521A JP 2021529521 A JP2021529521 A JP 2021529521A JP WO2020025703 A5 JPWO2020025703 A5 JP WO2020025703A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- btn3a
- pharmaceutical composition
- seq
- isolated anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 101100480850 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TDA3 gene Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000003501 co-culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204480A JP2024028834A (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306050.8 | 2018-08-01 | ||
| EP18306050 | 2018-08-01 | ||
| EP19153992 | 2019-01-28 | ||
| EP19153992.3 | 2019-01-28 | ||
| PCT/EP2019/070693 WO2020025703A1 (en) | 2018-08-01 | 2019-07-31 | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204480A Division JP2024028834A (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533204A JP2021533204A (ja) | 2021-12-02 |
| JPWO2020025703A5 true JPWO2020025703A5 (un) | 2022-08-05 |
| JP7401166B2 JP7401166B2 (ja) | 2023-12-19 |
Family
ID=67470408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529521A Active JP7401166B2 (ja) | 2018-08-01 | 2019-07-31 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
| JP2023204480A Pending JP2024028834A (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204480A Pending JP2024028834A (ja) | 2018-08-01 | 2023-12-04 | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11987631B2 (un) |
| EP (1) | EP3830119A1 (un) |
| JP (2) | JP7401166B2 (un) |
| KR (1) | KR20210084426A (un) |
| CN (1) | CN113286819B (un) |
| AU (1) | AU2019312831A1 (un) |
| BR (1) | BR112021001776A2 (un) |
| CA (1) | CA3107933A1 (un) |
| CL (1) | CL2021000258A1 (un) |
| IL (1) | IL280563B1 (un) |
| MX (1) | MX2021001268A (un) |
| SG (1) | SG11202101038SA (un) |
| WO (1) | WO2020025703A1 (un) |
| ZA (1) | ZA202100819B (un) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013333A1 (en) * | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| CN113286819B (zh) * | 2018-08-01 | 2024-05-24 | 感应检查疗法公司 | 抗btn3a抗体及其在治疗癌症或感染性病症中的用途 |
| TW202313695A (zh) | 2021-09-15 | 2023-04-01 | 法商感應檢查療法公司 | 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途 |
| WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
| AU2022378932A1 (en) | 2021-10-27 | 2024-05-02 | Assistance Publique Hopitaux De Marseille | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
| WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
| WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CN101370830A (zh) * | 2005-09-26 | 2009-02-18 | 米德列斯公司 | 抗cd70的人单克隆抗体 |
| US20120064096A1 (en) | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
| SG177689A1 (en) | 2009-07-31 | 2012-02-28 | Organon Nv | Fully human antibodies to btla |
| US8680241B2 (en) | 2009-09-06 | 2014-03-25 | Protab Ltd. | Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof |
| LT2593128T (lt) | 2010-07-15 | 2018-06-25 | Adheron Therapeutics, Inc. | Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| CN117143814A (zh) * | 2014-11-17 | 2023-12-01 | 阿迪塞特治疗公司 | 工程化的γδ T细胞 |
| CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| CN113286819B (zh) * | 2018-08-01 | 2024-05-24 | 感应检查疗法公司 | 抗btn3a抗体及其在治疗癌症或感染性病症中的用途 |
| TW202313695A (zh) * | 2021-09-15 | 2023-04-01 | 法商感應檢查療法公司 | 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途 |
-
2019
- 2019-07-31 CN CN201980051396.3A patent/CN113286819B/zh active Active
- 2019-07-31 JP JP2021529521A patent/JP7401166B2/ja active Active
- 2019-07-31 KR KR1020217006171A patent/KR20210084426A/ko unknown
- 2019-07-31 US US17/264,507 patent/US11987631B2/en active Active
- 2019-07-31 SG SG11202101038SA patent/SG11202101038SA/en unknown
- 2019-07-31 EP EP19745618.9A patent/EP3830119A1/en active Pending
- 2019-07-31 AU AU2019312831A patent/AU2019312831A1/en active Pending
- 2019-07-31 CA CA3107933A patent/CA3107933A1/en active Pending
- 2019-07-31 BR BR112021001776-3A patent/BR112021001776A2/pt unknown
- 2019-07-31 WO PCT/EP2019/070693 patent/WO2020025703A1/en unknown
- 2019-07-31 MX MX2021001268A patent/MX2021001268A/es unknown
- 2019-07-31 IL IL280563A patent/IL280563B1/en unknown
-
2021
- 2021-01-29 CL CL2021000258A patent/CL2021000258A1/es unknown
- 2021-02-05 ZA ZA2021/00819A patent/ZA202100819B/en unknown
-
2022
- 2022-09-26 US US17/935,154 patent/US20230272080A1/en active Pending
-
2023
- 2023-06-01 US US18/327,127 patent/US11945871B2/en active Active
- 2023-12-04 JP JP2023204480A patent/JP2024028834A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3411410B1 (en) | Pd-1 antibodies | |
| CN109311966B (zh) | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 | |
| JP2638652B2 (ja) | カケクチンと反応するモノクロナール抗体 | |
| EP2964674B1 (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
| KR100236156B1 (ko) | 2중 특이 항체 이종이량체(Bispecific antibody heterodimers) | |
| US10597454B2 (en) | PD-1 antibodies | |
| JP2018537962A5 (un) | ||
| WO2019201133A1 (zh) | 神经生长因子的单克隆抗体及其编码基因和应用 | |
| EP3119806B1 (en) | Il-21 antibodies | |
| TWI612059B (zh) | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 | |
| RU2651776C2 (ru) | Биспецифические антитела против cd3*cd19 | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| JP2019537617A (ja) | インターロイキン１７ａを標的とする抗体、その製造方法及び応用 | |
| US10689434B2 (en) | Antibody against hepatitis B surface antigen and use thereof | |
| JPWO2020025703A5 (un) | ||
| KR102399028B1 (ko) | 이중-특이적 항원-결합 폴리펩티드 | |
| WO2019148405A1 (zh) | IL-4Rα抗体及其用途 | |
| JP2023542049A (ja) | インターロイキン－２ムテイン及びその使用 | |
| CN112930195A (zh) | 抗人Fn14抗体 | |
| CN112585169A (zh) | 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 | |
| WO2022214677A1 (en) | Anti-cd73 antibodies | |
| CN116178565A (zh) | 一种双特异性多肽复合物 | |
| CN113316587A (zh) | 一种双特异性分子及其制备与用途 | |
| RU2021104977A (ru) | Антитела против btn3a и их применение при лечении рака или инфекционных заболеваний | |
| WO2024077776A1 (zh) | 抗体突变方法在治疗性抗体药物中的应用 |